Effect of Low-Level Laser Therapy (LLLT) in Pulmonary Inflammation in Asthma Induced by House Dust Mite (HDM): Dosimetry Study

Abstract

Asthma is characterized by chronic inflammation in the airways. Several models have been proposed for the discovery of new therapies. Low-Level Laser Therapy (LLLT) is relatively new and effective, very low cost, with no side effects. However, there is still no consensus on the optimal dose to be used. In this sense, the objective of the present study was to evaluate the best dose in an experimental model of asthma induced by House Dust Mite (HDM). Balb/c mice received administration of 100 ug/animal HDM and LLLT applications (diode laser: 660 nm, 100 mW and four different energies 1J, 3J, 5J, and 7.5J) for 16 days. After 24 hours, we studied inflammatory, functional, and structural parameters. The results showed that LBI was able to modulate the pulmonary inflammation observed by reducing the number of cells in Bronchoalveolar Lavage Fluid (BALF) as well as reducing the percentage of neutrophils, eosinophils and T lymphocytes. On the other hand, LLLT increased the level of IL-10 and reduced levels of IL-4, IL-5 and IL-13 in BALF. LLLT was able to reduce the production of mucus, peribronchial eosinophils, collagen deposition, bronchoconstriction index, and bronchial and muscular thickening in the airways. We concluded that the use of LLLT in the treatment of chronic inflammation of the airways attenuated the inflammatory process and functional and structural parameters. We emphasize, in general, that the 1J and 3J laser presented better results. Thus, photobiomodulation may be considered a promising tool for the treatment of chronic pulmonary allergic inflammation observed in asthma.

Fotobiomodulação como coadjuvante no tratamento na lesão pulmonar aguda decorrente da sepse

“…Atualmente, é possível identificar diversos estudos sobre a PBM relativos a LPA, (Sergio et al, 2018), inflamação pulmonar (de Brito et al, de Lima et al, 2011), SDRA (Oliveira et al, 2014), estresse oxidativo pulmonar e alergia (Costa et al, 2016), asma (Rigonato-Oliveira et al, 2019), doença pulmonar obstrutiva crônica (da Cunha et al, 2018) Research, Society and Development, v. 9, n. 10, e5929109024, 2020 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v9i10.9024 dentre outros, devido à sua capacidade de reduzir substancialmente múltiplos marcadores moleculares e celulares da inflamação preservando a função pulmonar.…”

Phototherapy in Allergic Rhinitis: From In Vitro Studies to Clinical Trials

“…Another study evaluated the effect of LLLT (wavelength of 660 nm, power of 100 mW, energy of 1/3/5/7.5 J) on chronic pulmonary inflammation in mouse model of asthma induced by house dust mite (HDM). 21 The LLLT was able to modulate the pulmonary inflammation by reducing the number of cells in BAL fluid and reducing the percentage of neutrophils, eosinophils and T lymphocytes. On the other hand, LLLT increased the level of IL-10 and reduced levels of IL-4, IL-5 and IL-13 in BAL fluid.…”

Light-based technologies for management of COVID-19 pandemic crisis

“…[ [108] , [109] , [110] ]. There are currently 90 published papers on PBM concerning “acute lung injury” [ 110 ] OR “pulmonary inflammation” [ 111 ] OR “lung inflammation” [ 109 ] OR “ARDS” [ 112 ] OR “lung oxidative stress” [ 113 ] OR “asthma” [ 114 ] many involving small animal models where it can be argued that light penetrates more easily than in humans. Because COVID-19 involves a “cytokine storm”, PBM delivered to the torso (chest and back) might not only allow some light to reach the lungs but might also reduce the systemic inflammation responsible for COVID-19 sepsis-like syndrome [ 115 ] and disseminated intravascular coagulation [ 116 ] that can be deadly [ 117 ].…”